
Episode 20. Management of Myeloma in LMICs
Blood Cancer Talks
The Importance of Monitoring Myeloma Markers
After transplant, in myeloma, unfortunately, we cannot give them a treatment-free remission. So basically everybody is on revlimate at least for two to three years. And after that, if there has been two consequent MRD negative, then I discuss with the patient that to hold the limit and watch closely the myeloma markers. Although there is no randomized trial showing that approach is perfectly safe, but there are some single-arm trials now that's coming out.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.